Aarti Drugs Buyback worth Rs 60 crore to open on Sept. 11

Founded in 1984, Aarti Pharmaceuticals Ltd. is a member of the Aarti Group of Industries, which is worth $900 million. The company has a robust research and development division at Tarapur, Maharashtra Industrial Development Corporation (MIDC), which is close to its manufacturing locations. The company produces active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and chemicals. Formulas are also created by Pinnacle Life Science Private Limited, a wholly owned subsidiary. Products falling under APIs include, among others, ciprofloxacin hydrochloride, metronidazole, metformin HCL, ketoconazole, and ofloxacin; specialty chemicals include benzene sulphonyl chloride and methyl nitrate. The business is keen to expand volume after successfully securing a niche for itself over the years. It is anticipated that consumer spending on prescription drugs will rise as a result of the government’s efforts to support private health insurance plans, which will drive growth in the domestic generic market. GMP certification has been obtained by Aarti Drugs Ltd. for its manufacturing facilities. Furthermore, the organization is striving to achieve ISO 9002 compliance across all of its divisions; approval has already been granted to one of those divisions. Mix of Revenue: Seventy percent of revenue is derived from specialty chemicals, thirteen percent from formulations, five percent from intermediates, and the remaining portion from other sources. The majority of the therapeutic segment—47 percent—is made up of antibiotics, with the remaining categories being anti-protozol (17%), anti-inflammatory (11%), anti-diabetic (16%), anti-fungal (8%), and others (3%).

Details of buyback share from Aarti Drugs:

The plan is to repurchase up to 6,65,000 (six lakhs sixty-five thousand) equity shares of the company, which represents 0.72% of all equity shares in the company’s paid-up share capital, for a maximum consideration of Rs. 59,85,00,000 (Rupees Fifty-Nine Crores Eighty-Five Lakhs Only), payable in cash per equity share.

Aarti Drugs Ltd. stock price is slightly declining:

In advance of shares being bought back tomorrow, the stock price of Aarti Drugs Ltd. is currently trading at Rs. 543 per share, a slight decrease from earlier in the day.

Conclusion: Aarti Drugs’ buyback of its shares will ultimately benefit the business.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.